Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Related Clinical Trial
A Safety Study of GAMMAGARD LIQUID (GGL) in Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Hizentra® in Inflammatory Neuropathies – pHeNIx Study Proof-of-concept Study for BIVV020 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Subcutaneous Immunoglobulin in De-novo CIDP (SIDEC) InertiaLocoGraphy as a Biomarker of Immunoglobulin Therapy Efficacy in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy A Registered Cohort Study of Immune-Mediated Neuropathies Interest of Mycophenolate for CIDP Weaning Efficacy and Safety Study of I10E in Treatment of Patients With CIDP Transcriptome Analysis of the Peripheral Blood in CIDP Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP Safety and Efficacy Study of Three Different Dosages of NewGam in Patients With CIDP Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Subcutaneous Immunoglobulin for CIDP Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP The Evaluation of Efficacy and Safety of Rituximab in Refractory CIDP Patients With IgG4 Autoantibodies Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy MRI in Diagnosing and Monitoring CIDP High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Panzyga in CIDP Administered at Different Infusion Rates Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Brief Title

Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy

Official Title

A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Brief Summary

      The objective of this study is to demonstrate the efficacy and safety of Privigen in subjects
      with CIDP.
    


Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Responder Rate

Secondary Outcome

 Change in Adjusted INCAT Score

Condition

Chronic Inflammatory Demyelinating Polyneuropathy

Intervention

10% liquid formulation of human immunoglobulin

Study Arms / Comparison Groups

 IgPro10
Description:  10% liquid formulation of human immunoglobulin (IgPro10). IgPro10 will be administered by IV infusion as one induction dose of 2 g/kg body weight (bw), followed by seven 3-weekly maintenance doses of 1 g/kg bw.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Biological

Estimated Enrollment

31

Start Date

November 2010

Completion Date

November 2011

Primary Completion Date

November 2011

Eligibility Criteria

        Inclusion Criteria:

        IVIG-untreated subjects:

          -  Either subjects with newly diagnosed CIDP (developing over at least 2 months) or
             subjects with an IVIG treatment interruption for at least 1 year with a progressive
             disease (deteriorating in the last 2 months) prior to enrolment.

          -  Actual diagnosis (including electrophysiology) of CIDP with progressive or relapsing
             dysfunction from motor and sensory or symmetric motor nerve only in at least 1 limb
             resulting from neuropathy. Criteria for definite or probable CIDP according to
             EFNS/PNS guideline.

          -  Age ≥18 years.

          -  Male or female.

          -  Written informed consent for study participation obtained before undergoing any study
             specific procedures.

        IVIG-pretreated subjects:

          -  Being treated regularly with IVIG on a fixed cycle length of 2 to 6 weeks ± 5 days in
             the last 6 months, on a fixed dosage of ± 20 % in the last 6 months and deteriorating
             by at least 1 INCAT score point during the Washout Period of up to 10 weeks (except
             for an increase from 0 to 1 solely due to upper limb score).

          -  Historic diagnosis of CIDP with progressive or relapsing dysfunction from motor and
             sensory or symmetric motor nerve only in at least 1 limb resulting from neuropathy.
             Criteria for definite or probable CIDP according to EFNS/PNS guideline.

          -  Age ≥18 years.

          -  Male or female.

          -  Written informed consent for study participation obtained before undergoing any study
             specific procedures.

        Exclusion Criteria:

          -  A motor syndrome that fulfils criteria for multifocal motor neuropathy (MMN) with
             conduction block (i.e., upper limb motor weakness without sensory deficit and with a
             50% decrease in action potential amplitude or area on proximal compared with distal
             stimulation in motor nerves).

          -  CIDP with monoclonal gammopathy of uncertain significance (CIDP-MGUS) with anti-MGUS
             antibodies and patients with distal acquired demyelinating symmetric (DADS)neuropathy.

          -  Any disease (mainly neurological or chronic orthopedic) that may cause symptoms or may
             interfere with treatment or outcome assessments with the INCAT (e.g., diphtheria, drug
             or toxin exposure and diabetes mellitus likely to have caused the neuropathy, IgM
             paraproteinemia, familial neuropathy, borreliosis with radiculopathy,
             post-polio-syndrome,M. Parkinson, stroke).

          -  Current malignancy.

          -  History of cardiac insufficiency (New York Heart Association [NYHA] III/IV),
             cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or
             advanced ischemic heart disease, congestive heart failure or severe hypertension.

          -  History of thrombotic episodes (deep vein thrombosis, myocardial infarction,
             cerebrovascular accident).

          -  Migraine associated with IVIG infusion in the last 3 months prior to enrolment.

          -  Known allergic or other severe reactions to blood products including intolerability to
             previous IVIG (i.e. severe headache, hypersensitivity, intravascular hemolysis).

          -  Subjects with serum IgA level less than 50% of the lower normal limit.

          -  Known hyperprolinemia.

          -  Any condition (including alcohol, drug or medication abuse) that is likely to
             interfere with evaluation of the study product or satisfactory conduct of the study.

          -  Plasma exchange 3 months prior to enrolment.

          -  Treatment with immunomodulatory agents others than steroids, methotrexate or
             azathioprine (e.g. interferon, TNF-α inhibitors) within 6 months before enrolment.

          -  Treatment with rituximab in the 12 months before enrolment.

          -  Abnormal laboratory parameters: creatinine > 1.5 times the upper normal limit (UNL),
             lactate dehydrogenase (LDH) > 1.5 times the UNL, C-reactive protein (CRP) > 1.5 times
             the UNL, hemoglobin (Hb) < 10 g/dL.

          -  Ongoing HIV, hepatitis C and hepatitis B infection.

          -  Participation in another clinical study (or use of another investigational medicinal
             product [IMP]) within 3 months prior to enrolment

          -  Not able to comply with study procedures and treatment regimen.

          -  Employee at the study site, or spouse/partner or relative of any study staff (e.g.,
             investigator, sub-investigators, or study nurse).

          -  Pregnancy or nursing mother.

          -  Intention to become pregnant during the course of the study.

          -  Female subjects of childbearing potential either not using, or not willing to use, a
             medically reliable method of contraception for the entire duration of the study, or
             not sexually abstinent for the entire duration of the study, or not surgically
             sterile.
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Program Director Clinical R&D, , 

Location Countries

Belgium

Location Countries

Belgium

Administrative Informations


NCT ID

NCT01184846

Organization ID

IgPro10_3001

Secondary IDs

1504

Responsible Party

Sponsor

Study Sponsor

CSL Behring


Study Sponsor

Program Director Clinical R&D, Study Director, CSL Behring


Verification Date

March 2013